Are monoclonal antibodies against the interleukin-6 receptor effective in patients who are critically ill with COVID-19?
In patients who are critically ill with COVID-19 and require respiratory or cardiovascular organ support, the monocloncal antibodies tocilizumab and sarilumab reduce mortality (number needed to treat [NNT] = 12) and decrease the need for organ support during the 3 weeks following the initiation of therapy. As we have seen with other studies of COVID-19 therapies, benefit is often restricted to specific groups, and this result should not be generalized to less ill patients for whom the benefit has not been demonstrated.
- How do ibuprofen, ketorolac, and diclofenac compare for the treatment of acute, nonradicular low back pain in adults?
- Is there an association between gastric cancer and the use of proton pump inhibitors?
- Is leukocyte-rich plasma less effective than leukocyte-poor plasma when injected into the knees of adults with osteoarthritis?
- Is an intramuscular glucocorticoid injection noninferior to an intra-articular glucocorticoid injection in reducing knee pain in adults with knee osteoarthritis?
- Are postoperative opioids more effective than nonopioids in reducing pain after minor or moderate surgical procedures?
Leave A Comment